There will be a royalty payment as part of the deal, so the more indications that trofinetide can be used for the more royalties Neuren will get. It all depends on wether cash will be given to Neuren to fund trials for other indications or weather the pharma company takes that responsibility and Neuren just focus on getting nnz-2591 to market. Neuren have done a good job recruiting and executing trials so they might retain the gig - who knows.
If it works on Rett and Fragile X then it may well help regular autism which would make it a potential block buster drug.
https://www.statista.com/statistics/676354/autism-rate-among-children-select-countries-worldwide/
This chart shows why the Japanese patent protection is so valuable.
Cannot understand $4 a share....., page-91
-
- There are more pages in this discussion • 77 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.47 |
Change
0.610(3.07%) |
Mkt cap ! $2.583B | |||
| Open | High | Low | Value | Volume |
| $20.00 | $20.49 | $19.94 | $2.532M | 125.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 140 | $20.46 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.48 | 61 | 2 |
View Market Depth
| Last trade - 11.54am 12/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |